📰 Adjuvant News
Page 2 - Adjuvant News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Adjuvant. Real-time updates on events, politics, business and more.
October 9, 2023
SCHLIEREN, Switzerland, October 09, 2023--LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorr
September 26, 2023
Adjuvant therapy, instead of just surgery alone, for early-stage non-small-cell lung cancer (NSCLC) after surgery incurs lower medical costs than surgery alone.
August 27, 2023
GSK's Arexvy vaccine for RSV can remain effective against a range of variants and produces strong antibody responses against distinct viral strains.
July 20, 2023
Rachel Layman, MD, summarizes how to dose CDK4/6 inhibitors in different clinical settings.
July 6, 2023
Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the monarchE trial, which evaluated abemaciclib plus endocrine therapy for HR+, HER2 negative, node positive, high-risk early breast cancer.
June 30, 2023
Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis-free vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma
June 5, 2023
Wind and uncertain weather can add challenges to herbicide application. Morris Henry, Helena Agri-Enterprises, LLC talks on combatting those hurdles.
June 5, 2023
WASHINGTON (dpa-AFX) - Biopharmaceutical company Novavax, Inc. (NVAX), which advances protein-based vaccines with its novel Matrix-M adjuvant, announced on Monday that it has signed a three-year
June 4, 2023
Treatment with adjuvant TAGRISSO reduced the risk of death by more than half ... | June 4, 2023
May 25, 2023
Evaxion developed a genetic adjuvant technology that boosts the immune responses of viral, bacterial and cancer vaccinesPreclinically validated for both DNA and mRNA vaccines, and ready for clinical testing